Diamond Hill Capital Management Inc. Makes New $394.01 Million Investment in Zoetis Inc. $ZTS

Diamond Hill Capital Management Inc. purchased a new position in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,692,799 shares of the company’s stock, valued at approximately $394,010,000. Zoetis comprises about 1.9% of Diamond Hill Capital Management Inc.’s holdings, making the stock its 14th biggest position.

Other institutional investors have also modified their holdings of the company. Savvy Advisors Inc. grew its position in Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after purchasing an additional 1,114 shares during the last quarter. Chicago Partners Investment Group LLC grew its holdings in Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after buying an additional 1,961 shares in the last quarter. CIBC Asset Management Inc increased its position in Zoetis by 4.3% in the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Nordea Investment Management AB raised its stake in Zoetis by 10.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock valued at $368,245,000 after acquiring an additional 214,889 shares in the last quarter. Finally, Ninety One UK Ltd raised its stake in Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Pelican Bay Capital Management increased its stake and is betting on Zoetis to benefit from the expanding pet care market — a vote of confidence from an institutional investor that can support the stock. Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market
• Positive Sentiment: The board declared a second‑quarter cash dividend of $0.53 per share (annualized yield ~1.7%; ex‑dividend Apr 20, payable Jun 2). The payout supports income investors and signals steady free cash flow. Zoetis Declares Second Quarter 2026 Dividend
• Positive Sentiment: Analyst coverage from Zacks highlights Zoetis as likely to beat upcoming earnings estimates and flags it as a momentum stock — positive near‑term catalyst if results meet expectations. Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
• Neutral Sentiment: Coverage pieces note the stock’s year‑to‑date underperformance versus the broader market, though analysts remain cautiously bullish — indicating upside is dependent on execution rather than sentiment alone. Do Wall Street Analysts Like Zoetis Stock?
• Neutral Sentiment: Market calendars note Zoetis is projected to report quarterly results this week — an event that could be a catalyst either way depending on beats or guidance. Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday
• Negative Sentiment: A valuation/analysis piece cautions that Zoetis’ 2026 outlook is tempered by softer pet clinic visits and increased regulatory scrutiny, which could pressure revenue growth and multiples if trends persist. Zoetis (ZTS) Valuation Check As 2026 Outlook Is Tempered On Softer Pet Visits And Regulatory Scrutiny

Zoetis Stock Up 0.5%

Shares of Zoetis stock opened at $127.40 on Friday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The firm has a market capitalization of $56.14 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 2.20 and a beta of 0.96. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The stock’s fifty day moving average is $123.96 and its 200-day moving average is $136.31.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.69%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ZTS. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average price target of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.